Literature DB >> 27900088

Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report.

Fumiyasu Hanamura1, Yoshihiro Shibata2, Tsuyoshi Shirakawa3, Miyuki Kuwayama3, Hisanobu Oda4, Hiroshi Ariyama5, Kenichi Taguchi6, Taito Esaki3, Eishi Baba7.   

Abstract

Colorectal cancer (CRC) has a propensity to metastasize to the liver, lungs and regional abdominal lymph nodes, but rarely to the bone marrow. A 60-year-old man presented to the National Hospital Organization Kyushu Cancer Center with a 4-week history of persistent lower back pain, anorexia and difficulty defecating. Complete blood count revealed severe thrombocytopenia and erythroblastosis, suggesting a hematological malignancy. However, the bone marrow examination demonstrated involvement by a moderately to poorly differentiated adenocarcinoma, but no hematopoietic abnormalities. A computed tomography scan revealed thickening of the wall of the sigmoid colon, with para-aortic, hilar, mediastinal and supraclavicular lymphadenopathy. The patient was thus diagnosed with sigmoid colon adenocarcinoma with lymph node and bone marrow metastasis. Modified FOLFOX6 was promptly initiated, with concurrent therapy for disseminated intravascular coagulation (DIC). An increased number of thrombocytes was observed on day 6. After 3 cycles of treatment, the patient recovered from DIC and the levels of serum carcinoembryonic antigen and cytokeratin 19 fragment were decreased. Tumor biopsy during colonoscopy following recovery from DIC demonstrated poorly differentiated adenocarcinoma with mucin production, without mutations in the RAS, BRAF or PIK3CA genes, and a cytokeratin (CK) 7-negative, CK20-positive phenotype. The patient has been treated with chemotherapy for 150 days without disease progression. However, the efficacy of chemotherapy for rarely encountered bone marrow metastasis from CRC is poor. The present case was favorably maintained on chemotherapy and survived for 10 months.

Entities:  

Keywords:  bone marrow metastasis; chemotherapy; colon cancer; disseminated intravascular coagulation

Year:  2016        PMID: 27900088      PMCID: PMC5103869          DOI: 10.3892/mco.2016.1029

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  21 in total

Review 1.  Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds.

Authors:  Pierre A Coulombe; Pauline Wong
Journal:  Nat Cell Biol       Date:  2004-08       Impact factor: 28.824

2.  Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors.

Authors:  Fatima A Haggar; Robin P Boushey
Journal:  Clin Colon Rectal Surg       Date:  2009-11

3.  Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas.

Authors:  Reyhan Bayrak; Sibel Yenidünya; Hacer Haltas
Journal:  Pathol Res Pract       Date:  2011-02-01       Impact factor: 3.250

4.  BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

Authors:  Reetesh K Pai; Priya Jayachandran; Albert C Koong; Daniel T Chang; Shirley Kwok; Lisa Ma; Daniel A Arber; Raymond R Balise; Raymond R Tubbs; Bonnie Shadrach; Rish K Pai
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

5.  Bone marrow necrosis caused by metastatic colon cancer.

Authors:  Yung-Chih Wang; Ping-Ying Chang; Nai-Shun Yao
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

6.  CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

Authors:  Piero Dalerba; Debashis Sahoo; Soonmyung Paik; Xiangqian Guo; Greg Yothers; Nan Song; Nate Wilcox-Fogel; Erna Forgó; Pradeep S Rajendran; Stephen P Miranda; Shigeo Hisamori; Jacqueline Hutchison; Tomer Kalisky; Dalong Qian; Norman Wolmark; George A Fisher; Matt van de Rijn; Michael F Clarke
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245

7.  Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.

Authors:  G Wiedswang; E Borgen; R Kåresen; G Kvalheim; J M Nesland; H Qvist; E Schlichting; T Sauer; J Janbu; T Harbitz; B Naume
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

8.  Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients.

Authors:  J Y Pierga; L Deneux; C Bonneton; A Vincent-Salomon; C Nos; P Anract; H Magdelénat; P Pouillart; J P Thiery
Journal:  Int J Biol Markers       Date:  2004 Jan-Mar       Impact factor: 2.659

9.  Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.

Authors:  Lisa Pleyer; Philip Went; Gudrun Russ; Erika Prinz; Viktoria Faber; Hans-Joachim Röwert; Renate Karlbauer; Richard Greil
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 10.  Bone marrow metastases. A review.

Authors:  R J Papac
Journal:  Cancer       Date:  1994-11-01       Impact factor: 6.860

View more
  2 in total

1.  Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab.

Authors:  Takehito Ehara; Masato Kitazawa; Nao Hondo; Shugo Takahata; Yuta Yamamoto; Makoto Koyama; Motohiro Okumura; Satoshi Nakamura; Shigeo Tokumaru; Futoshi Muranaka; Yusuke Miyagawa; Yuji Soejima
Journal:  Case Rep Oncol       Date:  2020-02-17

2.  Occult colon cancer with sepsis as the primary manifestation identified by bone marrow puncture: A case report.

Authors:  Hua-Jun Wang; Chen-Jie Zhou
Journal:  World J Clin Cases       Date:  2022-03-26       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.